KPIs & Operating Metrics(New)
Additions To Property And EquipmentAdjusted Income Before TaxAdjusted Income Before Tax By SegmentAssets By SegmentBreakdown Of AssetsCardiovascular/Metabolism/Other RevenueCardiovascular/Metabolism/Other Revenue AnnualConsumer RevenueContractual BoligationsCost Of Products SoldDisaggregated Revenue Mix %Disaggregated RevenuesEarnings Before Taxes On IncomeEbt By SegmentEbt By Segment AnnualEbt Margin By Segment Annual %Employee StatisticsFacilites By RegionGross Margin %Gross ProfitImmunology RevenueImmunology Revenue AnnualInfectious Diseases RevenueInfectious Diseases Revenue AnnualInnovative Medicine Revenue Breakdown AnnualInternational Sales By SegmentInterventional Solutions Revenue AnnualInventoriesLong Lived Assets By RegionMedical Devices RevenueMedical Devices Revenue AnnualMedtech Revenue Breakdown AnnualNeurosciences RevenueNeurosciences Revenue AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Oncology RevenueOncology Revenue AnnualOpex As A % Of RevenueOPEX SegregationOrthopaedics Revenue AnnualPharmaceutical Revenue BreakdownProperty And Equipment SegregationPulmonary Hypertension RevenuePulmonary Hypertension Revenue AnnualRevenue By ProductRevenue By Product %Revenue By RegionRevenue By Region %Revenue By Region (Annual)Revenue By Region (Annual) %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Square Footage By RegionSurgery Revenue AnnualUs Sales By SegmentVision Revenue Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Johnson & Johnson (JNJ) Gross Profit (2009 - 2026)

Johnson & Johnson recorded quarterly Gross Profit of $16.0 billion in Q1 2026, down 3.86% quarter-over-quarter from $16.6 billion in Q4 2025, and up 9.77% year-over-year from $14.5 billion in Q1 2025.

Johnson & Johnson's Gross Profit history runs 18 years deep, the most recent figure standing at $16.0 billion for Q1 2026.

  • In Q1 2026, Gross Profit rose 9.77% year-over-year to $16.0 billion; the TTM figure through Mar 2026 stood at $65.4 billion (up 7.12% YoY), while the FY2025 annual figure was $63.9 billion, up 4.22% from the prior year.
  • Gross Profit came in at $16.0 billion for Q1 2026 at Johnson & Johnson, down from $16.6 billion in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $16.7 billion in Q3 2025 to a low of $13.8 billion in Q2 2022.
  • A 5-year average of $15.0 billion and a median of $14.9 billion in 2024 frame the typical range for Gross Profit.
  • Across the five-year window, Gross Profit decreased 14.07% in 2022 and rose 9.77% in 2026, its largest moves.
  • Johnson & Johnson's Gross Profit stood at $13.8 billion in 2022, then rose by 5.59% to $14.6 billion in 2023, then climbed by 5.45% to $15.4 billion in 2024, then rose by 7.82% to $16.6 billion in 2025, then slipped by 3.86% to $16.0 billion in 2026.
  • According to Business Quant data, Gross Profit over the past three periods registered $16.0 billion, $16.6 billion, and $16.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.